Estimation, testing and sample size calculation within the responder-stratified exponential survival model
The primary endpoint in phase III oncology trials is usually overall survival, where differences between therapies may only be observable after many years. To avoid withholding of a promising therapy, preliminary approval based on a surrogate endpoint is possible. The approval can be confirmed later...
Guardado en:
| Autores principales: | , , |
|---|---|
| Formato: | Article (Journal) |
| Lenguaje: | inglés |
| Publicado: |
24 Apr 2026
|
| In: |
Journal of biopharmaceutical statistics
Year: 2026, Pages: 1-23 |
| ISSN: | 1520-5711 |
| DOI: | 10.1080/10543406.2026.2655413 |
| Acceso en línea: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1080/10543406.2026.2655413
|
| Notas de Autor: | Samuel Kilian, Marietta Kirchner, and Meinhard Kieser |
Search Result 1
Estimation, testing and sample size calculation within the responder stratified exponential survival model
2023
- Resolving-System, kostenfrei
- Resolving-System, kostenfrei
- Verlag, kostenfrei, Volltext
- Resolving-System, kostenfrei
- Langzeitarchivierung Nationalbibliothek, kostenfrei
Book/Monograph
Tesis
Online Resource
Search Result 2